Literature DB >> 11124817

Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.

L Spahr1, J P Villeneuve, H K Tran, G Pomier-Layrargues.   

Abstract

The diagnosis of refractory ascites in cirrhotic patients carries a poor prognosis and liver transplantation should always be considered in this situation. Identification of patients who will not respond to diuretic therapy usually requires several weeks of observation during which a trial of diuretics is instituted using stepwise increases in dosage in order to classify ascites as refractory. In the present study we evaluated the effect of a single dose of 80 mg intravenous furosemide on urinary sodium excretion over 8 hours in cirrhotic patients with ascites responsive to diuretic treatment (group 1; n = 14) and patients with refractory ascites (group 2; n = 15). The test was performed after 3 days without diuretics and patients were on a 80 mEq sodium/day diet. Refractory ascites was defined by the absence of response after 3 months of high doses of diuretics (spironolactone 200 mg/d + furosemide 80 mg/d + metolazone 2.5 mg/d) and the need for repeated paracentesis. The two groups had similar degrees of liver and renal dysfunction as assessed by the Pugh score and creatinine clearance. The effects of furosemide on 8-hour natriuresis was much higher in patients with responsive ascites as compared with patients with refractory ascites (125 +/- 46 vs. 30 +/- 16 mEq; mean +/- SD; P <.0001). A natriuresis lower than 50 mEq/8 hours was observed in all group-2 patients as compared with none from group 1. The present study shows that patients with refractory ascites can be identified quickly and accurately by using this simple furosemide-induced natriuresis test, which could be very useful to select patients for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11124817     DOI: 10.1053/jhep.2001.20646

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusion.

Authors:  Pierluigi Toniutto; Mario Pirisi; Carlo Fabris; Luca Apollonio; Kalliopi Sereti; Ettore G Bartoli
Journal:  Dig Dis Sci       Date:  2006-10-20       Impact factor: 3.199

2.  Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Authors:  Xiaoyuan Xu; Zhongping Duan; Huiguo Ding; Wengang Li; Jidong Jia; Lai Wei; Enqiang Linghu; Hui Zhuang
Journal:  Hepatol Int       Date:  2019-01-18       Impact factor: 6.047

3.  Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites.

Authors:  Mohammed Abdelhamid El-Bokl; Bahaa Eldeen Senousy; Khaled Zakaria El-Karmouty; Inas El Khedr Mohammed; Sherif Monier Mohammed; Sherif Sadek Shabana; Hassan Shalaby
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

Review 4.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

5.  The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis.

Authors:  Nimer Assy; Mohib Kayal; Yoram Mejirisky; Miguel Gorenberg; Osamah Hussein; Sorina Schlesinger
Journal:  BMC Gastroenterol       Date:  2006-11-29       Impact factor: 3.067

6.  Markers of diuretic resistance in emergency department patients with acute heart failure.

Authors:  Andrew Doering; Cathy A Jenkins; Alan B Storrow; JoAnn Lindenfeld; Gregory J Fermann; Karen F Miller; Matthew Sperling; Sean P Collins
Journal:  Int J Emerg Med       Date:  2017-05-08

7.  Role of diuretics and ultrafiltration in congestive heart failure.

Authors:  Dmitry Shchekochikhin; Fawaz Al Ammary; Jo Ann Lindenfeld; Robert Schrier
Journal:  Pharmaceuticals (Basel)       Date:  2013-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.